Current Status and Future Perspective of Postoperative Treatment for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Overview

Journal Jpn J Clin Oncol

Publisher Oxford University Press

Specialty Oncology

Date 2024 Mar 7

PMID 38452121

Authors

Naomi Kiyota

Makoto Tahara

Akihiro Homma

Affiliations

Soon will be listed here.

Abstract

Surgery remains a foundation of treatment for locally advanced squamous cell carcinoma of the head and neck. For postoperative patients at high risk of recurrence, however, surgery by itself is not enough, and improvement in survival requires postoperative treatment. Unlike the case with most other malignancies, the standard postoperative treatment for locally advanced squamous cell carcinoma of the head and neck patients with high-risk factors for recurrence is radiotherapy or chemoradiotherapy with cisplatin. However, chemoradiotherapy with cisplatin at a dose of 100 mg/m2 once every 3 weeks has raised discussion over insufficient cisplatin delivery due to high-dose-related toxicity. As a possible solution, a recent randomized trial of the JCOG1008 has proved the non-inferiority of postoperative chemoradiotherapy with weekly cisplatin at a dose of 40 mg/m2 to 3-weekly cisplatin in terms of overall survival. Here, this review article focuses on current evidence and future perspectives of postoperative treatment for locally advanced squamous cell carcinoma of the head and neck.

Citing Articles

Challenging Recurrence and Management of Squamous Cell Carcinoma in the Calcaneal Region: A Case Report.

Tang M, Nguyen T, Le H, Nguyen H, Tran N, Le M Cureus. 2024; 16(4):e59087.

PMID: 38803760 PMC: 11128329. DOI: 10.7759/cureus.59087.

References

Tsan D, Lin C, Kang C, Huang S, Fan K, Liao C . The comparison between weekly and three-weekly cisplatin delivered concurrently with radiotherapy for patients with postoperative high-risk squamous cell carcinoma of the oral cavity. Radiat Oncol. 2012; 7:215. PMC: 3564896. DOI: 10.1186/1748-717X-7-215. View

Bernier J, Cooper J, Pajak T, Van Glabbeke M, Bourhis J, Forastiere A . Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005; 27(10):843-50. DOI: 10.1002/hed.20279. View

Sun X, Tao Y, Le Tourneau C, Pointreau Y, Sire C, Kaminsky M . Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study. Lancet Oncol. 2020; 21(9):1173-1187. DOI: 10.1016/S1470-2045(20)30327-2. View

Rampino M, Ricardi U, Munoz F, Reali A, Barone C, Musu A . Concomitant adjuvant chemoradiotherapy with weekly low-dose cisplatin for high-risk squamous cell carcinoma of the head and neck: a phase II prospective trial. Clin Oncol (R Coll Radiol). 2010; 23(2):134-40. DOI: 10.1016/j.clon.2010.09.004. View

Burtness B, Harrington K, Greil R, Soulieres D, Tahara M, de Castro Jr G . Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019; 394(10212):1915-1928. DOI: 10.1016/S0140-6736(19)32591-7. View

Cooper J, Pajak T, Forastiere A, Jacobs J, Campbell B, Saxman S . Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004; 350(19):1937-44. DOI: 10.1056/NEJMoa032646. View

Argiris A, Karamouzis M, Johnson J, Heron D, Myers E, Eibling D . Long-term results of a phase III randomized trial of postoperative radiotherapy with or without carboplatin in patients with high-risk head and neck cancer. Laryngoscope. 2007; 118(3):444-9. DOI: 10.1097/MLG.0b013e31815b48f4. View

Bauml J, Vinnakota R, Anna Park Y, Bates S, Fojo T, Aggarwal C . Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck. J Natl Cancer Inst. 2018; 111(5):490-497. PMC: 6510226. DOI: 10.1093/jnci/djy133. View

Smid L, Budihna M, Zakotnik B, Soba E, Strojan P, Fajdiga I . Postoperative concomitant irradiation and chemotherapy with mitomycin C and bleomycin for advanced head-and-neck carcinoma. Int J Radiat Oncol Biol Phys. 2003; 56(4):1055-62. DOI: 10.1016/s0360-3016(03)00207-4. View

10.

Harari P, Harris J, Kies M, Myers J, Jordan R, Gillison M . Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. J Clin Oncol. 2014; 32(23):2486-95. PMC: 4121506. DOI: 10.1200/JCO.2013.53.9163. View

11.

Strojan P, Vermorken J, Beitler J, Saba N, Haigentz Jr M, Bossi P . Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review. Head Neck. 2015; 38 Suppl 1:E2151-8. DOI: 10.1002/hed.24026. View

12.

Noronha V, Joshi A, Patil V, Agarwal J, Ghosh-Laskar S, Budrukkar A . Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial. J Clin Oncol. 2017; 36(11):1064-1072. DOI: 10.1200/JCO.2017.74.9457. View

13.

FLETCHER G, Evers W . Radiotherapeutic management of surgical recurrences and postoperative residuals in tumors of the head and neck. Radiology. 1970; 95(1):185-8. DOI: 10.1148/95.1.185. View

14.

Rischin D, King M, Kenny L, Porceddu S, Wratten C, Macann A . Randomized Trial of Radiation Therapy With Weekly Cisplatin or Cetuximab in Low-Risk HPV-Associated Oropharyngeal Cancer (TROG 12.01) - A Trans-Tasman Radiation Oncology Group Study. Int J Radiat Oncol Biol Phys. 2021; 111(4):876-886. DOI: 10.1016/j.ijrobp.2021.04.015. View

15.

Bachaud J, Cohen-Jonathan E, Alzieu C, David J, Serrano E, Daly-Schveitzer N . Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys. 1996; 36(5):999-1004. DOI: 10.1016/s0360-3016(96)00430-0. View

16.

Ferris R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19):1856-1867. PMC: 5564292. DOI: 10.1056/NEJMoa1602252. View

17.

Laramore G, Scott C, Al-Sarraf M, Haselow R, Ervin T, Wheeler R . Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. Int J Radiat Oncol Biol Phys. 1992; 23(4):705-13. DOI: 10.1016/0360-3016(92)90642-u. View

18.

Holoye P, Grossman T, Toohill R, Kun L, Byhardt R, Duncavage J . Randomized study of adjuvant chemotherapy for head and neck cancer. Otolaryngol Head Neck Surg. 1985; 93(6):712-7. DOI: 10.1177/019459988509300604. View

19.

Peters L, Goepfert H, Ang K, Byers R, Maor M, Guillamondegui O . Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial. Int J Radiat Oncol Biol Phys. 1993; 26(1):3-11. DOI: 10.1016/0360-3016(93)90167-t. View

20.

Morse R, Ganju R, TenNapel M, Neupane P, Kakarala K, Shnayder Y . Weekly cisplatin chemotherapy dosing versus triweekly chemotherapy with concurrent radiation for head and neck squamous cell carcinoma. Head Neck. 2019; 41(8):2492-2499. DOI: 10.1002/hed.25717. View